The medical landscape for chronic rhinosinusitis is rapidly advancing, with new treatments offering hope for improved quality of life for patients. As pharmaceutical companies race to develop ...

The probability of revision sinus surgery including the removal of nasal polyps is higher if the patient has asthma or is on antibiotics at the time of their initial surgery. However, higher age was ...

An adenomatous polyp in which malignant cells have invaded beyond the muscularis mucosa into the submucosa may still be curable by colonoscopic polypectomy under specific conditions, depending on the ...

Please provide your email address to receive an email when new articles are posted on . Twelve-year data were available for 71 patients, or 85.5% of the assessed study population. Around 55% of those ...

SAN DIEGO -- Tezepelumab (Tezspire) reduced nasal polyps and symptoms in severe chronic rhinosinusitis while also decreasing need for further treatments, the WAYPOINT trial showed. The monoclonal ...

On Saturday, Amgen Inc (NASDAQ:AMGN) and AstraZeneca Plc (NASDAQ:AMGN) announced full results from the Phase 3, registrational WAYPOINT trial evaluating the efficacy and safety of tezepelumab in ...

Findings showed treatment with tezepelumab significantly reduced the size of nasal polyps and nasal congestion compared with placebo. The Food and Drug Administration (FDA) has approved Tezspire ® ...